Fang Jianwei, Lv Chao and Yuan Chenhao of Zhong Lun Law Firm in Shanghai explain the background and impact – including on multinational companies – of a set of new rules governing the local production of imported drugs
June 03, 2024
Technology Media and Telecom
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
May 29, 2024Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
May 23, 2024Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
May 22, 2024Procedures are facilitated for marketing of domestically produced foreign pharmaceuticals
May 17, 2024Successful U.S. IPO of Chinese EV brand suggests rising investor confidence, but regulatory risks still loom; Burberry wins trademark infringement and unfair competition lawsuit; and China proposes guidelines to it's lithium battery sector amid overcapacity concerns.
May 16, 2024SAMR specifies details on collecting electronic evidence
May 06, 2024Although CFIUS reviews have become more challenging for Chinese companies, transactions could still go ahead with a few tips in mind.
April 30, 2024China lifts foreign investment restrictions on value-added telecommunications services
April 25, 2024
